Health Plans Juggle the Hope, High Costs of Rare Disease Drugs
At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs. As more rare disease therapies come to market, health plans are often evaluating products for conditions they have never…